HC Wainwright reaffirmed their buy rating on shares of Onconova Therapeutics (NASDAQ:ONTX) in a research note published on Thursday, MarketBeat Ratings reports. HC Wainwright currently has a $7.50 price objective on the biopharmaceutical company’s stock, up from their previous price objective of $6.00.

A number of other equities analysts have also commented on the stock. Maxim Group lowered shares of Onconova Therapeutics from a buy rating to a hold rating in a research report on Wednesday, January 17th. Zacks Investment Research raised shares of Onconova Therapeutics from a sell rating to a hold rating in a research report on Wednesday, January 10th. One investment analyst has rated the stock with a sell rating, two have issued a hold rating and three have assigned a buy rating to the company. Onconova Therapeutics presently has an average rating of Hold and a consensus price target of $7.83.

Shares of Onconova Therapeutics (NASDAQ ONTX) traded up $0.06 during midday trading on Thursday, reaching $1.14. 92,365 shares of the company’s stock traded hands, compared to its average volume of 442,960. The company has a market capitalization of $21.12, a P/E ratio of -0.41 and a beta of 0.22. Onconova Therapeutics has a twelve month low of $0.95 and a twelve month high of $3.88.

In related news, major shareholder 683 Capital Management, Llc bought 200,000 shares of Onconova Therapeutics stock in a transaction dated Thursday, February 8th. The shares were acquired at an average cost of $1.04 per share, with a total value of $208,000.00. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Company insiders own 27.30% of the company’s stock.

A hedge fund recently raised its stake in Onconova Therapeutics stock. 683 Capital Management LLC increased its holdings in shares of Onconova Therapeutics Inc (NASDAQ:ONTX) by 24.0% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 464,934 shares of the biopharmaceutical company’s stock after purchasing an additional 89,934 shares during the period. 683 Capital Management LLC owned approximately 4.32% of Onconova Therapeutics worth $697,000 at the end of the most recent quarter. Institutional investors own 25.27% of the company’s stock.

COPYRIGHT VIOLATION WARNING: This article was first reported by Watch List News and is owned by of Watch List News. If you are accessing this article on another site, it was stolen and reposted in violation of US & international copyright & trademark law. The legal version of this article can be viewed at https://www.watchlistnews.com/hc-wainwright-reaffirms-buy-rating-for-onconova-therapeutics-ontx/1906965.html.

Onconova Therapeutics Company Profile

Onconova Therapeutics, Inc is a clinical-stage biopharmaceutical company. The Company operates through the identification and development of oncology therapeutics segment. It is focused on discovering and developing small molecule drug candidates to treat cancer. The Company has created a targeted anti-cancer agents designed to work against specific cellular pathways that are important to cancer cells.

Receive News & Ratings for Onconova Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Onconova Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.